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ABSTRACT
There is a major problem from asthma in Japan due 
to its high prevalence, morbidity, economic cost and
mortality. The striking feature of the time trends in
asthma mortality in Japan is the two epidemics of
asthma mortality in young people that occurred at the
same time as similar epidemics in a number of other
countries. These epidemics are likely to be due, at least
in part, to the overuse of specific β-adrenergic recep-
tor agonist drugs, namely isoprenaline and fenoterol.
Following recent warnings by the Japanese Ministry of
Health and Welfare against the use of fenoterol and
the resulting reduction in fenoterol sales, together with
other changes in management consistent with the 
recommendations of the Japanese Asthma Guidelines,
the asthma mortality rate has again fallen in Japan.
However, Japan still has case fatality rates that are
disproportionately greater than those in other coun-
tries. One approach that can be taken to reduce 
the high asthma mortality rate in Japan is to develop
and implement a community based asthma self-
management plan system of care whereby patients 
are provided with a practical system by which they 
can assess the severity of their asthma, a treatment
regimen for both long-term therapy and management
of a severe attack, and written guidelines provided by
their medical practitioners in which assessment and
treatment are integrated in a simple format. In con-
trolled studies, this management approach has been
shown not only to markedly reduce asthma mortality,
in terms of reduction in hospital admissions and
nocturnal wakening, but also to markedly reduce mor-
tality from asthma. The Japanese Asthma Guidelines
have advocated this approach, which is referred to 
as the ‘asthma management zone system’. Through
implementation of this system of care, together with
other management initiatives, it is likely that the 
mortality rate from asthma will fall further over forth-
coming years.
Key words: asthma, epidemic, guidelines, Japan,
mortality, self-management.
INTRODUCTION
Japan is a country with a major burden from asthma in
terms of prevalence, morbidity and mortality.1–3 Indeed,
the recent International Study of Asthma and Allergies in
Childhood (ISAAC) program, the first standardized inter-
national study of the prevalence of asthma symptoms in
children, has identified that Japan has the highest preva-
lence of asthma in Asia, similar to that of many European
countries1,2 (Table 1). This finding was observed with both
the written and video questionnaires, suggesting that 
the high prevalence rate is likely to be real and not due 
to language or cultural issues relating to the inter-
pretation of the written questionnaire. There are also data
to suggest that asthma prevalence has increased
markedly in Japan over recent decades,4,5 a trend that
has been observed in numerous countries worldwide.6
The prevalence of atopy, as measured by the presence of
allergen-specific IgE antibodies, has also increased over
recent decades in Japan7 and internationally.8 While it 
is recognized that such increases are due to changes in
environmental risk factors, there is incomplete under-
standing of the relative importance of the numerous
factors that have been implicated.
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Japan also experiences considerable morbidity from
asthma, as indicated by the high prevalence of symptoms
of severe asthma. In the ISAAC program, the proportion
of teenage children in Japan reporting at least four
attacks of asthma per year was 4.2%, whereas the pro-
portion of children who had experienced current severe
asthma symptoms, defined as wheezing of sufficient
severity to limit speech in the past 12 months, was 2.1%.1
These figures indicate the major burden of severe asthma
in Japanese children.
In terms of mortality in the representative 5–34-year-old
age group, Japan has a disproportionately high rate com-
pared with other countries.9 This is particularly evident
when national case fatality rates are derived from the ratio
of the asthma mortality rates to the prevalence rates of
severe asthma for each country. This analysis shows that
not only did Japan have a relatively high absolute mortality
rate in the 1990s, but the proportion of severe asthmatics
who died was considerably greater than other countries
(Table 2). While the mortality rate has reduced significantly
in the late 1990s, the case fatality rate remains dispropor-
tionately greater than other countries.
It is possible to approach the problem of asthma
mortality in Japan in a number of different ways. The
approach undertaken in the present review is to first con-
sider what is known about the trends in asthma mortality
in Japan, review the circumstances associated with a fatal
outcome in asthma and explore how this information can
be used to develop strategies that overcome these prob-
lems of management.
TRENDS IN ASTHMA MORTALITY IN JAPAN
The striking feature of the time trends in asthma mortality
in Japan is the two ‘epidemics’ of asthma mortality in
young people that occurred at the same time as similar
epidemics in a number of other countries3,9–12 (Fig. 1). In
the 1960s, epidemics of asthma mortality occurred in at
least six countries and this was attributed to the overuse of
the high-dose preparation of isoprenaline, isoprenaline
forte.9,12,13 In Japan, the forte preparation of isoprenaline
was not marketed and only a modest increase in 
asthma mortality was observed in the 5–34-year-old age
Fig. 1 Asthma mortality per 100 000 in persons aged 
5–34 years in Japan, 1950–1997.
Table 1 The prevalence of self-reported wheezing in the
past 12 months in 13–14-year-old children
Prevalence (%)
Indonesia 2.1
China 4.2
Taiwan 5.2
India 6.0
South Korea 7.7
Pakistan 8.5
Malaysia 9.6
Singapore 9.7
Philippines 12.3
Hong Kong 12.4
Thailand 13.0
Japan 13.4
Table 2 Comparison of asthma mortality rates with
prevalence rates of severe asthma in 12 countries
Asthma Prevalence of Ratio
mortality rate* severe asthma†
Australia 0.86 8.3 0.10
Canada 0.25 8.0 0.03
England
and Wales 0.52 8.7 0.06
Finland 0.21 3.1 0.07
France 0.40 2.8 0.14
Italy 0.23 2.0 0.12
Japan 0.73 2.1 0.35
New Zealand 0.50 8.0 0.06
Sweden 0.12 2.0 0.06
US 0.47 10.0 0.05
West Germany 0.44 5.7 0.08
*Asthma mortality rate (per 100 000) in persons aged 5–34 years in
1993.
†Asthma prevalence rates defined as self-reported episodes of
wheezing sufficient to limit speech in the previous 12 months, in
13–14-year-old children, 1993–1995. (Adapted from ISAAC Steering
Committee.1)
Note, mortality and prevalence data are not available in the same
age group.
group.3,10,11 However, there was a fivefold increase in
asthma mortality in the 10–14-year-old age group that par-
alleled the increase in total sales of β-adrenergic receptor
agonist aerosols. In 1972, the Japan Ministry of Public
Welfare made β-adrenergic receptor agonist aerosols pre-
scription drugs, sales decreased and the death rate fell in
both the 5–34- and 10–14-year-old age groups.
In the mid-1970s to 1980s, a second asthma mortality
‘epidemic’ occurred in New Zealand, linked to the use 
of the high-dose preparation of fenoterol.9,12 Although
similar epidemics were not reported elsewhere, in many
countries mortality increased during this period and, in
some, the magnitude of the increase was substantial. In
Japan, the death rate began to increase again in the
1980s, approximately doubling during this decade.3,11
A review of drug use by patients who died from asthma 
in Japan reported that fenoterol was the β-adrenergic
receptor agonist used by just over one-half of patients, at
a time when it had only an 18% market share.3 While
recognizing the limitations of these data, these figures
yielded a relative risk of asthma death of fivefold in indi-
viduals prescribed fenoterol in Japan, an estimate
consistent with those from case-control studies from New
Zealand and Canada11,14 (Table 3). The time trend data
in Japan also show a parallel between asthma mortality
in persons aged 5–34 years since the mid-1980s and
both the increase of sales of fenoterol since its introduc-
tion in 1985 and total β-adrenergic receptor agonist
sales. In recognition of concerns regarding the role 
of fenoterol in asthma mortality, the Japanese Ministry 
of Health and Welfare cautioned that ‘. . . the use of
fenoterol MDI should be avoided in children as possible’.
Following this warning and the resulting reduction in
fenoterol sales, together with other changes in man-
agement consistent with the recommendations of the
Japanese Asthma Guidelines,15–18 the asthma mortality
rate has again fallen in Japan.
Considered together with epidemiologic studies in
other countries, these findings suggest that the major
trends in asthma mortality in Japan over the past 40 years
may well be due, at least in part, to the overuse of isopre-
naline and fenoterol.14 The findings also demonstrate the
hazards of these specific β-adrenergic receptor agonist
drugs, which should no longer be used in the treatment of
asthma.19
CIRCUMSTANCES OF DEATH FROM ASTHMA
The findings from asthma mortality surveys undertaken in
many countries throughout the world have consistently
identified the same factors associated with management
that have contributed to a fatal outcome12,20–24 (Table 4).
The most important observation has been that, in the
fatal episode, patients did not recognize or respond
appropriately to the severity to their life-threatening
attack of asthma, thereby leading to an inevitable delay
in seeking emergency medical help. As a result, most
patients who die from asthma are in extremus before they
seek medical help. The reasons for the lack of recognition
of the potential life-threatening nature of the attack are
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Table 3 Proportion of cases (asthma deaths) and controls prescribed fenoterol in studies in New Zealand, Saskatchewan and
Japan†
Total % of cases % of controls Relative risk of 95% CI
deaths on fenoterol on fenoterol death (OR)
First New Zealand study 117 51.3 40.4 1.6 1.0–2.3
Second New Zealand study 58 51.7 35.7 1.9 1.1–3.4
Third New Zealand study 112 59.8 45.9 1.8 1.2–2.7
Saskatschewan study 44 47.7 15.9 4.8 2.5–9.3
Japanese study12 30 53.4 18.3* 5.1 2.6–9.9
†Modified from Beasley et al.14
*Market share; this study did not include a formal control group.
OR, odds ratio; CI, confidence interval.
Table 4 Management problems associated with fatal
attacks of asthma
Fatal attack
Delay in seeking medical help
Inability to recognize the severity of the attack
Overreliance on bronchodilator therapy
Insufficient systemic steroid use
Lack of written guidelines for management
Long term
Lack of appreciation of chronic asthma severity and risk of
death
Poor compliance with management
Discontinuity of medical care
Underutilization of inhaled corticosteroids
that the patients have commonly not been given clear
written guidelines as to how to recognize a severe attack,
do not have an objective method of assessment, such 
as peak flow monitoring, and obtain a false sense 
of reassurance through the frequent use of high-dose 
β-adrenergic receptor agonist inhaler, providing tempo-
rary but short-lived bronchodilation.
This problem has been identified in the recent Japanese
asthma mortality surveys, in which the relationship
between asthma death and overreliance or excessive
dependence on β-adrenergic receptor agonists has been
stressed.3,20,25,26 These reports also made the important
point that this excessive dependence on β2-adrenergic
receptor agonists contributed to other factors associated
with a fatal outcome, such as delay in seeking emergency
hospital treatment. Case reports of excessive use have
been striking, with some patients using up to one canister
of their β-adrenergic receptor agonist inhaler in the week
preceding death, without seeking medical assistance.
Furthermore, a recent case-control study identified that
excessive dependence on β2-adrenergic receptor agonists
was more than twice as common in asthmatic patients
who died, than in those experiencing a near fatal attack.27
Similar problems have been identified in terms of 
the long-term management of patients who die from
asthma.12,16,21–23 Patients and their relatives do not per-
ceive that they are at risk of an adverse outcome, are
poorly compliant with their regular therapy, often do not
receive inhaled corticosteroid therapy and are infrequent
attenders at their usual medical care.
These difficulties with the acute life-threatening attack
and long-term management can be grouped into three
main areas.
1. Inability to assess asthma severity, either in terms 
of chronic asthma severity or the severity of the life-
threatening attack of asthma.
2. Inadequate treatment with insufficient inhaled corti-
costeroid use long term, or oral steroid use in the severe
attack, with the associated overreliance on β-adrenergic
receptor agonist therapy.
3. Poor communication between patients and their
doctors resulting in poor compliance, discontinuity of
medical care and lack of written guidelines indicating
what the patient should do in a severe attack.
MANAGEMENT STRATEGIES
One approach to reduce mortality is to develop manage-
ment strategies that specifically address and overcome
these three main groups of problems that have been
identified as contributing to fatal asthma. In this way, a
management strategy would need to be based on the
following three principles.
1. A practical system to allow patients to assess the
severity of their asthma.
2. A treatment regimen for both long-term therapy
and management of the severe attack.
3. Written guidelines provided by the medical practi-
tioner in which assessment and treatment are integrated
in a simple format.
Assessment
Fundamental to the success of this strategy is the ability of
patients to recognize a deterioration in asthma control.
This requires the assessment of asthma severity through
the educated interpretation of key symptoms and mea-
surements of lung function.28,29 The development of
nocturnal wakening is recognized to be a good marker of
unstable asthma, whereas the poor response to the
increased use of inhaled β-adrenergic receptor agonist
therapy is an important marker of a severe attack requir-
ing medical treatment. Measurements of peak flow at
home, with values expressed as a percentage of normal
predicted or previous best achieved recordings, are also
recommended for the objective assessment of the degree
of airflow obstruction. Peak flow monitoring is of particu-
lar importance in severe asthmatics, because they have
been shown to have the worst perception of asthma
severity.30
Treatment
As outlined in the Japanese Asthma Guidelines, pharma-
cologic therapy of asthma can be based on a step-wise
approach in accordance with asthma of differing severity.
It is recommended that, for most patients with persistent
asthma, inhaled corticosteroid agents represent the basis
of long-term therapy, with the dose varied according to
asthma severity. Indeed, inhaled corticosteroids represent
the only medication that has been shown to improve lung
function, symptom control, quality of life, reduce the
frequency and severity of attacks, and reduce the risk of
asthma mortality.31,32
Inhaled β-adrenergic receptor agonists are the bron-
chodilator drugs of choice, with patients advised that they
should be used ‘as required’ to reverse episodes of symp-
tomatic asthma and that the increased requirement for
inhaled β-adrenergic receptor agonist therapy indicates
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worsening asthma.28,29 In severe attacks, the asthmatic
patient is advised to seek medical help and start oral cor-
ticosteroids according to a predetermined plan. One
regimen that is now commonly used is for patients to take
30–40 mg/day prednisone until the patient returns to
baseline and then take 15–20 mg/day prednisone for the
same number of days. This regimen ensures that the asth-
matic patient starts oral steroids early in the course of an
exacerbation without being committed to an unnecessar-
ily long course.
WRITTEN GUIDELINES
The provision of written guidelines in which self-
assessment is used as the basis for changes in treatment
requires the establishment of a self-management plan
system of care. A number of different plans have been
developed, based on the four-stage prototype outlined in
Table 5.33–36 In many respects, the first two stages can be
considered to provide guidelines for the long-term
management of asthma. In particular, the instructions to
vary the dose of inhaled corticosteroid treatment in a
step-wise manner in accordance with changes in asthma
severity represents one practical method whereby the
recommendations for the long-term treatment of chronic
persistent asthma in adults can be implemented. The
third and fourth stages provide guidelines for the treat-
ment of severe asthma, with intensive treatment started 
by the patient in an attempt to prevent the development 
of a life-threatening attack. Thus, self-management 
plans represent one way in which the recommendations
for acute severe and chronic persistent asthma can be
brought together in a single framework.
The Japanese Asthma Guidelines have advocated 
this approach, which is referred to as the ‘asthma man-
agement zone system’.16 The principal difference in the
Japanese system compared with the prototype outlined
above is that it is based on three rather than four stages.
In this way, the Japanese plan provides for the patient to
recognize three stages of asthma severity, which are
coded with the colors of a traffic signal light. The green
zone indicates that asthma is under control and stable; 
if the patient’s condition remains in this zone for at least 
3 months, a careful step-down in long-term therapy can
be considered. The yellow zone indicates caution, when
the patient notices increasing asthma symptoms and the
peak expiratory flow (PEF) falls to between 50 and 80% 
of predicted or best values. The patient is advised that 
this yellow zone signifies that an acute asthma attack is
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in progress or that long-term asthma control is deterio-
rating. The treatment options in this zone include an
increased use of inhaled β2-adrenergic receptor agonist
therapy, increasing the dose of inhaled corticosteroids
and/or a short course of oral steroids with medical
review. The red zone signifies a medical alert, with
asthma symptoms at rest, a minimal response to inhaled
β-adrenergic receptor agonist and PEF values less than
50%. In this situation, the patient is advised to take high
doses of their inhaled β-adrenergic receptor agonist drug
while they seek emergency medical review.
EFFICACY
Despite the consensus on both the necessity and the
principles underlying the development of asthma self-
management plans, it is only recently that their efficacy
has been clearly established. The best assessment of 
their efficacy can be obtained from the recent system-
atic review of the literature,37 which identified that self-
management involving provision of a written action plan
led to a two-thirds reduction in hospitalizations for
asthma, whereas less intensive interventions did not
work. Similar findings were observed with respect to
emergency hospital visits, in which the provision of a
written action plan led to a 50% reduction. In studies
that compared peak flow with symptom-based manage-
ment plans,37 equivalent efficacy was observed in terms
of the proportion of subjects requiring hospitalization,
emergency room treatment or an unscheduled visit to
the doctor. There were no significant differences found
in studies in which a comparison was made between
those plans in which there was self-adjustment of
medication by the patient according to written, pre-
determined criteria, or on the basis of regular review by
a doctor.37
Importantly, the use of asthma self-management plans
has also been shown to markedly reduce mortality from
asthma.38 In this case-control study from Australia, the
provision of a written action plan was associated with a
70% reduction in the risk of death.
ISSUES REQUIRING CLARIFICATION
Although the efficacy of the asthma self-management
plan system of care has been demonstrated, there are a
number of issues that have yet to be clarified, as outlined
in Table 6. While clarification will be obtained for some
of these issues when specific studies are undertaken,
some features, such as which components of the plan
lead to the best clinical outcomes, may prove difficult to
unravel, because the different features of the plans are so
closely interrelated. The evidence to date suggests that it
is likely that the greatest benefit from self-management
plans will be obtained with the close integration of the
different features of self-assessment and management.
In recommending the use of asthma self-management
plans, it is also important to recognize that the require-
ments of individual asthmatic patients may vary con-
siderably and that no single plan is likely to be suitable 
for every patient. As a result, the amount of detail plans
provide, the specific drug treatment recommended at
each stage and the percentage reduction in peak flow, or
severity of symptoms chosen for the different therapeutic
responses recommended, may need to vary, depending
on the specific characteristics and needs of the asthmatic
patient.
IDENTIFICATION OF PATIENTS AT RISK
Finally, it is necessary to identify those patients at high risk
of a severe or life-threatening attack of asthma to ensure
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Table 6 Issues relating to the structure and implementation of asthma self-management plans that require further clarification
No. stages/levels (e.g. two-, three- vs four-stage plans)
Specific peak flow percentages indicating each stage (e.g. < 60 or 70% to start oral steroids)
Specific symptoms indicating each stage (e.g. nocturnal asthma, increasing β-adrenergic receptor agonist use and/or symptoms of
a cold for recognizing worsening)
Role of other medications (e.g. long-acting β-adrenergic receptor agonists, leukotriene antagonists, theophylline, sodium
cromoglycate/nedocromil)
The relationship between specific therapeutic responses and outcome (e.g. does increasing inhaled steroid dose in worsening
asthma prevent further deterioration?)
Which forms for different patient groups (e.g. adults vs children)
Methods of implementation (e.g. doctor vs other health professionals)
Intensity of implementation (e.g. how much peak flow and symptom monitoring is optimal?)
that they receive special attention in terms of their
ongoing medical management. A number of clinical
characteristics associated with such an increased risk
have been identified, relating to the presence of severe
disease, characteristics of the patient or problems associ-
ated with the utilization of medical care15,23,39–42 (Table 7).
The most practical and useful ways in which a clinician
can recognize high-risk asthmatic patients is to iden-
tify those requesting repeat prescriptions of two or more
β-adrenergic receptor agonist inhalers per month, those
who frequently visit their general practitioners or emer-
gency departments with severe asthma or patients who
have had a recent hospital admission. For example, a
patient who has had a hospital admission for asthma in
the previous year has a 16-fold increased risk of a fatal
attack of asthma.40 Among such patients, the marker that
is associated with the highest risk of death is a previous
admission to an intensive care unit for asthma and, in
particular, the requirement for mechanical ventilation,
which has a 5 year mortality rate of up to 20%.43
A complementary approach is to identify those char-
acteristics of individuals that put them at risk in terms of
the way in which they manage their asthma or utilize
medical care. These features include teenagers, those
from disadvantaged socioeconomic groups and those
with psychosocial problems or psychiatric disorders.44,45
The range of psychosocial factors that adversely affect
asthma management and have been identified to be
associated with near fatal or fatal asthma is extensive.
One simple way of recognizing such patients is to identify
those with current or recent use of major tranquillisers or
sedatives, which is associated with an increased risk of a
near fatal attack or death.46,47
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